[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"severe-acute-malnutrition-in-childhood\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:severe-acute-malnutrition-in-childhood":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100619535","treatment-of-severe-acute-malnutrition-in-children-6-to-59-months-old-with-standard-ready-to-use-therapeutic-food-compared-to-a-newly-formulated-lipid-optimized-ready-to-use-therapeutic-food-100619535",false,"NCT07345884","Treatment of Severe Acute Malnutrition in Children 6 to 59 Months Old With Standard Ready To Use Therapeutic Food Compared to a Newly Formulated Lipid Optimized Ready To Use Therapeutic Food","Comparison of Treatment of Severe Acute Malnutrition in Children 6 to 59 Months Old With Standard Ready To Use Therapeutic Food and Newly Formulated Lipid Optimized Ready To Use Therapeutic Food an Individual Randomized Double Blind Controlled Trial","Inclusion Criteria:\n\n* Children aged 6-59 months with severe acute malnutrition, i.e., MUAC \\\u003C11.5 cm, and\u002For weight-for-height\u002Flength z-score \\\u003C -3, and\u002For with bilateral pitting edema, with an appetite to completely consume a 30 g test feeding, and without medical complications presenting at selected rural therapeutic feeding health facilities\n\nExclusion Criteria:\n\n* Children that are simultaneously involved in another research trial or supplemental feeding program, are developmentally delayed, have vision or hearing deficits, or have a history of milk or peanut allergy.\n* Chronic diseases such as malabsorption, chronic kidney disease, inflammatory bowel disease, congenital heart disease, endocrine disorders (e.g., hypothyroidism, growth hormone deficiencies), recurrent infections (e.g., pneumonia, cough, fever, pharyngitis), chronic respiratory diseases (e.g., asthma, lung diseases), congenital or acquired immunodeficiency, and neurological disorders","ALL","6 Months","59 Months",{"count":20,"type":21},125,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this randomized clinical trial is to learn if a newly formulated Lipid-Optimized Ready-to-Use Therapeutic Food (LO-RUTF) can treat severe acute malnutrition in children aged 6 to 59 months. The main questions it aims to answer are:\n\n1. Does LO-RUTF impact physical recovery from severe acute malnutrition in participants?\n2. Does LO-RUTF impact neurocognitive performance after 8 and 12 weeks of treatment?\n\nResearchers will compare LO-RUTF to standard RUTF see if our energy-dense food compares to standard issue RUTF in terms of promoting recovery from severe acute malnutrition.\n\nParticipants will\n\n* Take a one-week ration of LO-RUTF or standard RUTF based on the participant's weight\n* Return every week for checkups, tests and to receive the next ration of assigned RUTF if eligible\n* Be assessed for neurocognitive function through Malawi Developmental Assessment Tool (MDAT) at three time points (before treatment, 4 weeks, 12 weeks)",[27,28,29],"Severe Acute Malnutrition in Childhood","Malnutrition, Child","Neurocognition, Child",[31,32],"RUTF","Ready-to-use therapeutic food","NOT_YET_RECRUITING","2026-04-20",{"date":36,"type":37},"2026-04-22","ACTUAL",{"date":39,"type":21},"2026-06",{"date":41,"type":21},"2026-10",{"name":43,"class":44},"University of California, Los Angeles","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":45},"100578909","phase-4-opportunistic-pneumococcal-immunisation-trial-in-malnutrition-100578909","NCT06817421","Opportunistic Pneumococcal Immunisation Trial in MALnutrition","Immunogenicity of Opportunistic Pneumococcal Conjugate Vaccination (Pneumosil®) Versus Control (Typhoid Conjugate Vaccine, Typbar TCV®) in Children Aged 6-59 Months Hospitalised With Severe Acute Malnutrition: a Single-centre, Double-blind, Randomised Controlled Trial in Timor-Leste","OPTIMAL","Inclusion Criteria:\n\n1. Aged 6-59 months at the time of hospitalisation\n2. Hospitalised with severe acute malnutrition (SAM, defined as any one of a, b, or c):\n\n   1. weight-for-length\u002Fheight z-score \\\u003C-3; or\n   2. middle upper arm circumference \\\u003C11.5cm; or\n   3. bilateral pitting pedal oedema unexplained by other causes\n3. Parent\u002Fcarer is willing for their child to participate in the study and has provided written informed consent\n4. Parent\u002Fcarer is willing to comply with all study procedures outlined in the protocol, including specimen collection, for the duration of the study\n\nExclusion Criteria:\n\n1. Known history of allergy or hypersensitivity to any component of either study vaccine, including diphtheria toxoid, or a history of anaphylactic shock.\n2. Treatment with another investigational drug or other intervention in the 30 days prior to randomisation, or ongoing participation in another clinical trial.\n3. Suspected primary or secondary immunodeficiency or prolonged administration (\\>14 days) of an immune modifying drug (including oral glucocorticoids) in the past 3 months.\n4. Known terminal illness expected to result in death within 6 months.\n5. Participants who, in the opinion of the site Principal Investigator, are unable to comply with the study protocol, including scheduled visits, assessments, and any other protocol-required procedures.\n6. Previously enrolled in this trial.",{"count":55,"type":21},214,[57],"PHASE4","The goal of the OPTIMAL clinical trial is to learn if a dose of a pneumococcal conjugate vaccine (PCV) generates a good immune response in young children who are in hospital with severe acute malnutrition.\n\nResearchers will compare an intervention group who get a dose of a PCV (Pneumosil) to a control group who get a dose of a Typhoid conjugate vaccine (Typbar TCV). To ensure all participants receive timely potential benefits, at 3 months participants in the intervention group with receive a dose of Typbar TCV, and those in the conrol group will receive a dose of Pneumosil.\n\nParticipants will be visited 4 times at their homes over six months after vaccination, with a phone review at 12 months after vaccination.",[27,60,61,62,63],"Pneumococcal Disease","Pneumococcal Vaccines","Pneumococcal Infection","Pneumonia in Children",[65,66,67,68,69,70,71],"Pneumococcal","Severe Acute Malnutrition in childhood","Pneumococcal vaccine","Pneumosil","Pneumococcal disease","Pneumococcal infection","Pneumonia","2025-12-10",{"date":74,"type":37},"2025-12-18",{"date":76,"type":21},"2026-01",{"date":78,"type":21},"2029-02",{"name":80,"class":44},"Nick Fancourt",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":45},"100576178","phase-3-severe-acute-malnutrition-and-child-development-clinical-trial-in-mwanza-100576178","NCT06781918","Severe Acute Malnutrition and Child Development Clinical Trial in Mwanza","BRAIN DEVELOPMENT, GROWTH AND HEALTH IN CHILDREN WITH SEVERE ACUTE MALNUTRITION","BRIGHTSAM","Inclusion Criteria:\n\n1. Age from 6-36 months.\n2. Consent given by a caregiver older than 18 years.\n3. Diagnosed with severe acute malnutrition (MUAC\\<115 mm, or WHZ ≤-3 or bipedal pitting edema).\n4. Eligible for RUTF treatment (expanded below).\n\nExclusion Criteria:\n\n1. Conditions preventing the child from receiving interventions, e.g., peanut butter allergy or cleft palate.\n2. Moderate or severe disability which significantly affects normal child development (e.g., cerebral palsy or hydrocephalus), identified using a standardized screening form.\n3. Children of families not living in the area or planning to move from the area within the follow-up period","36 Months",{"count":91,"type":21},800,[93],"PHASE3","This is a randomized clinical trial to learn whether ready-to-use therapeutic foods enriched with choline and docosahexaenoic acid (DHA) together with psychosocial stimulating activities work well to improve child development in children with severe acute malnutrition(SAM). The overall question this trial aims to answer is can the health and development outcomes of children with SAM be improved through optimized nutritional treatment and integrated psychosocial support.\n\nResearchers will compare the new ready-to-use therapeutic food and an integrated psychosocial stimulation to a standard look-alike nutritional supplement that contains no additional nutrients being investigated and the standard nutritional counseling given locally and assess its effects on child development in children with severe acute malnutrition.\n\nParticipants will:\n\n* Be given the trial interventions which will be delivered over 12 weeks\n* After the 12 weeks of intervention, participants will return for outcome evaluations (week 12 study visit), which will be repeated at follow-up visits after 24 and 48 weeks.",[27],[97,98,99,100,101,102],"Severe acute malnutrition","Ready to use therapeutic food","Childhood development","Psychosocial stimulation","Choline","Docosahexaenoic acid (DHA)","2025-01-13",{"date":105,"type":37},"2025-01-17",{"date":107,"type":21},"2025-02-03",{"date":109,"type":21},"2026-05-14",{"name":111,"class":112},"National Institute for Medical Research, Tanzania","OTHER_GOV"]